This technology is a series of compounds based on the structure of the small molecule, GC376, that inhibit the SARS-CoV-2 main protease and can be used as potential treatments for COVID-19.
Although vaccines are currently being used to limit the spread of COVID-19, few therapeutic targets against SARS-CoV-2 have been identified, and most have low clinical efficacy. Despite some therapeutics being used in clinical trials, none have been approved for treatment of COVID-19. The coronavirus main protease, 3CLpro or Mpro, is essential for maturation of the viral protein and has been noted as a potential drug target.
This technology describes a series of compounds based on the structure of GC376, a small molecule inhibitor, that could inhibit Mpro activity. The Mpro protease of SARS-CoV-2 directs viral replication and infection, making it an attractive target. This technology aims to develop small molecules with high selectivity for the viral protease that can serve as antiviral therapies for COVID-19 and related coronaviruses.
Patent Pending
IR CU21040
Licensing Contact: Beth Kauderer